Serine

Serine

SCHEMBL527447

N[C@@H](CO)C(=O)O.OB(O)O

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GGT1 P19440 4/20 0.52
▸ SLC1A1 P43005 3/20 0.52
▸ PTGS1 P23219 1/20 0.48
▸ SLC7A11 Q9UPY5 1/20 0.48
▸ ARG2 P78540 6/20 0.46
▸ ARG1 P05089 4/20 0.46
▸ GSR P00390 2/20 0.44
▸ GRIK1 P39086 2/20 0.44
▸ GRIK2 Q13002 2/20 0.44
▸ GRM1 Q13255 2/20 0.44
▸ GRM2 Q14416 2/20 0.44
▸ SLC1A3 P43003 2/20 0.44
▸ SLC1A2 P43004 2/20 0.44
▸ SLC7A5 Q01650 1/20 0.44
▸ GRM8 O00222 1/20 0.44
▸ GRM6 O15303 1/20 0.44
▸ GRIN2D O15399 1/20 0.44
▸ GRIN3B O60391 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44
▸ GRM5 P41594 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Serine SCHEMBL1681675 1.00 GGT1 (0.52) GGT1SLC1A1PTGS1SLC7A11ARG2
Serine SCHEMBL6929773 0.91 SLC1A1 (0.59) GGT1SLC1A1PTGS1SLC7A11GSR
Serine SCHEMBL2023740 0.91 SLC1A1 (0.59) GGT1SLC1A1PTGS1SLC7A11GSR
Serine SCHEMBL4455818 0.91 SLC1A1 (0.59) GGT1SLC1A1PTGS1SLC7A11GSR
(D)-Serine SCHEMBL43094 0.91 — —
Serine SCHEMBL1332181 0.91 — —
Serine SCHEMBL2023739 0.91 SLC1A1 (0.59) GGT1SLC1A1PTGS1SLC7A11GSR
Serine SCHEMBL6929758 0.91 SLC1A1 (0.59) GGT1SLC1A1PTGS1SLC7A11GSR
Serine SCHEMBL6520918 0.91 SLC1A1 (0.59) GGT1SLC1A1PTGS1SLC7A11GSR
(D)-Serine SCHEMBL6038168 0.91 SLC1A1 (0.59) GGT1SLC1A1PTGS1SLC7A11GSR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8715646-B2 Methods of determining need for anti-coagulation therapy THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2014-05-06 — — US disclosed
US-20130209435-A1 METHODS FOR PREDICTING RISK OF STROKE THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2013-08-15 — — US disclosed
EP-2598881-A2 METHODS FOR PREDICTING RISK OF STROKE The Board of Trustees of the University of Illinois (US) 2013-06-05 — — EP disclosed
WO-2012016150-A2 METHODS FOR PREDICTING RISK OF STROKE THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) 2012-02-02 — — WO disclosed
US-5332755-A Leukotriene antagonists as antiinflammatory agents and antiallergens BAYER AKTIENGESELLSCHAFT (DE) 1994-07-26 — — US disclosed
US-5221760-A Intermediates, leukotriene antagonists BAYER AKTIENGESELLSCHAFT (DE) 1993-06-22 — — US disclosed
US-5159097-A An arylphosphorous compound as chemical intermediate BAYER AKTIENGESELLSCHAFT (DE) 1992-10-27 — — US disclosed
US-5118700-A Leukotriene antagonist BAYER AKTIENGESELLSCHAFT (DE) 1992-06-02 — — US disclosed
EP-0341551-B1 ALKENOIC ACID DERIVATIVES BAYER AG (DE) 1992-04-01 — — EP disclosed
US-5041638-A Leucotriene antagonist; treatment of respiratory system disorders, cardiovascular disorders BAYER AKTIENGESELLSCHAFT (DE) 1991-08-20 — — US disclosed
EP-0341551-A1 Alkenoic acid derivatives BAYER AG (DE) 1989-11-15 — — EP disclosed
Send feedback